PuraPharm Plans HK$20 Million Convertible Bond Issue Under General Mandate

PuraPharm Corp. Ltd. ( (HK:1498) ) has issued an update.

PuraPharm Corporation Limited has entered into a conditional subscription agreement with an investor for the issue of HK$20 million in convertible bonds, which can be converted into shares at HK$0.49 each under its existing general mandate. The conversion shares will be listed on the Hong Kong Stock Exchange, while the bonds themselves will not be listed, and completion remains subject to regulatory and contractual conditions, leaving execution risk for shareholders and potential investors.

The transaction, if completed, will provide fresh capital and potential equity for PuraPharm without requiring a separate shareholder approval for a new mandate, aiding its financing flexibility. However, the prospective conversion implies possible future dilution for existing shareholders, and the company has warned investors that the deal may or may not proceed depending on whether all conditions, including listing approval for the conversion shares, are satisfied.

The most recent analyst rating on (HK:1498) stock is a Sell with a HK$0.33 price target. To see the full list of analyst forecasts on PuraPharm Corp. Ltd. stock, see the HK:1498 Stock Forecast page.

More about PuraPharm Corp. Ltd.

PuraPharm Corporation Limited is a Hong Kong–listed company engaged in the healthcare sector, focusing on products and services related to traditional Chinese medicine. The group targets the Greater China market, leveraging stock exchange listings in Hong Kong to support its capital and growth needs.

Average Trading Volume: 388,614

Technical Sentiment Signal: Sell

Current Market Cap: HK$173.9M

Find detailed analytics on 1498 stock on TipRanks’ Stock Analysis page.